Repligen stock is trading -31.46% below its average target price of $188.93 after dropping -2.0% during today's morning session. Analysts are giving the Mid-Cap Biotechnology company an average rating of buy and target prices ranging from $140.0 to $225.0 per share.
The stock has an above average percentage of its shares sold short at 8.5%, and a short ratio of 4.85. Since 6.44% of the company's shares are owned by insiders, we can infer that there is a degree of alignment between management and shareholder interests. Finally, we also note that a significant number of institutional investors are invested in the stock, with 103.3% of Repligen's shares being owned by this investor type.
Institutions Invested in Repligen
| Date Reported | Holder | Percentage | Shares | Value |
|---|---|---|---|---|
| 2024-12-31 | Price (T.Rowe) Associates Inc | 13% | 7,136,054 | $924,083,277 |
| 2024-12-31 | Blackrock Inc. | 12% | 6,857,260 | $887,980,850 |
| 2024-12-31 | Vanguard Group Inc | 9% | 5,101,090 | $660,565,624 |
| 2024-12-31 | State Street Corporation | 3% | 1,691,208 | $219,002,971 |
| 2024-12-31 | Champlain Investment Partners, LLC | 3% | 1,543,530 | $199,879,409 |
| 2024-12-31 | Sands Capital Management, LLC | 2% | 1,364,258 | $176,664,583 |
| 2024-12-31 | Bank Of New York Mellon Corporation | 2% | 1,351,264 | $174,981,925 |
| 2024-12-31 | Citadel Advisors Llc | 2% | 1,179,502 | $152,739,605 |
| 2024-12-31 | Macquarie Group Limited | 2% | 1,099,876 | $142,428,437 |
| 2024-12-31 | Impax Asset Management Group plc | 2% | 1,051,939 | $136,220,835 |
Besides an analyst consensus of strong upside potential, other market factors point to there being mixed market sentiment on Repligen.
